Immunovant (IMVT) vs Kymera Therapeutics (KYMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunovant (IMVT) has outperformed Kymera Therapeutics (KYMR) over the past year, gaining 98.9% versus a gain of 90.4%. Over five years, IMVT leads with a +267.4% price change compared with +89.4% for KYMR. Kymera Therapeutics is the larger company by market cap ($8.99 billion vs $6.25 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMVT | KYMR |
|---|---|---|
| Share price | $30.26 | $109.30 |
| Market cap | $6.25B | $8.99B |
| 1-day change | -5.56% | +0.88% |
| YTD return | +26.04% | +39.25% |
| 1-year return | +98.88% | +90.35% |
| 5-year return | +267.43% | +89.42% |
| EPS (TTM) | $-2.82 | $-3.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $39.21M |
| Revenue growth (YoY) | — | -16.70% |
| Net income (latest FY) | $-505.61M | $-311.35M |
| Gross margin | — | 0.00% |
| Operating margin | — | -891.07% |
| Net margin | — | -794.04% |
| 52-week high | $45.42 | $130.05 |
| 52-week low | $16.08 | $55.26 |
| Distance from 52-week high | -33.38% | -15.96% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +61.53% | +27.47% |
| Average volume | 1.22M | 698.42K |
| Shares outstanding | 206.55M | 82.26M |
| Employees | 315 | 273 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 273 employees
IMVT vs KYMR FAQ
Which is bigger, Immunovant or Kymera Therapeutics?
Kymera Therapeutics (KYMR) is larger, with a market capitalization of $8.99B compared with $6.25B for Immunovant (IMVT).
Which stock has performed better over the past year, IMVT or KYMR?
IMVT returned +98.88% over the past 12 months, compared with +90.35% for KYMR (price return, excluding dividends). Past performance does not predict future results.
Are Immunovant and Kymera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.